Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Ice Chips for Oxaliplatin-Induced Cold Sensitivity
NCT03427021Phase 1Terminated
- Sponsor
- Abramson Cancer Center
- Start
- Feb 2017
- Primary completion
- Oct 2018
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in Cold intolerance, sponsored by Abramson Cancer Center. Primary endpoint: Overall intraoral cold sensitivity score at 6 months. Started Feb 2017; status: terminated.
02
Conditions
Cold intolerance
Beyond the preview
Go deeper on NCT03427021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03427021.